This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Here's Why You Should Hold On to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) expects to witness foreign exchange headwinds in 2020.
Here's Why You Should Hold On to Inogen (INGN) Stock for Now
by Zacks Equity Research
Inogen (INGN) expects to report a loss per share in the first quarter of 2020.
PerkinElmer (PKI) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
PerkinElmer (PKI) introduces test for the detection of coronavirus after it receives EUA for the same.
OPKO's BioReference Laboratories Widens COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from growing product pipeline, strong R&D focus and strategic acquisitions.
Here's Why Investors Should Buy Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) sees a slew of developments lately.
Masimo & University Hospitals Unite for Patient Monitoring
by Zacks Equity Research
Masimo (MASI) sees a plethora of developments lately.
OPKO's BioReference Laboratories Widens COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
PRA Health's New Program to Lend Support to Healthcare System
by Zacks Equity Research
PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.
Here's Why You Should Hold on to NextGen Healthcare Stock Now
by Zacks Equity Research
NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and robust demand for other NextGen solutions.
MCK vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MCK vs. COO: Which Stock Is the Better Value Option?
Here's Why You Should Retain Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margin remains a woe.
NextGen's New Platform Set to Improve Patient Engagement
by Zacks Equity Research
The availability of NextGen's (NXGN) Patient Experience Platform is likely to enable high-quality healthcare and drive patient engagement.
Here's Why You Should Buy Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) lifts adjusted earnings per share view for fiscal 2020.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show
by Sreyoshi Mukherjee
The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.
Coronavirus-Affected MedTech Drags S&P 500 Index Down
by Trina Mukherjee
Amid uncertainty surrounding the coronavirus outbreak, here are a few S&P 500 MedTech stocks that took a hit.
Cooper Companies (COO) Misses on Q1 Earnings, Lifts View
by Zacks Equity Research
Cooper Companies (COO) gains from core CVI segment in fiscal Q1.
Cooper Cos. (COO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of -0.74% and -0.26%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cooper Companies (COO) Q1 Earnings?
by Zacks Equity Research
Cooper Companies (COO) fiscal first-quarter performance is likely to reflect better-than-expected performance at CVI and CSI, and higher revenues.
PCTEL (PCTI) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
PCTEL's (PCTI) fourth-quarter performance is likely to have benefited from robust 5G scanning receiver business.
Ciena (CIEN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ciena's (CIEN) fiscal first-quarter performance is likely to have benefited from its global scale and diversification across geographies and customer segments.
Is a Beat in Store for ABM Industries' (ABM) Q1 Earnings?
by Zacks Equity Research
ABM Industries' (ABM) first-quarter fiscal 2020 revenues are likely to have benefited from organic growth.
Analysts Estimate Cooper Cos. (COO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cooper Cos. (COO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Cooper Cos. (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.